Skip to main content
SpringerLink
Log in
Book cover

Abdominal Sepsis pp 225–239Cite as

Evolving Treatment Strategies for Severe Clostridium difficile Colitis: Defining the Therapeutic Window

  • Chapter
  • First Online:

Part of the book series: Hot Topics in Acute Care Surgery and Trauma ((HTACST))

Abstract

All hospital systems should recognize that Clostridium difficile colitis is a major healthcare-associated infection that can progress to life-threatening severity if not recognized and treated early. The management of severe Clostridium difficile colitis remains controversial, and the therapeutic modalities are evolving rapidly along with the bacteria. In this chapter we will identify stages of severe C. difficile colitis and determine when surgical consultation and which therapies may be appropriate for each stage. We will also illustrate the key elements to the use of intracolonic vancomycin therapy at the beginning of the “therapeutic window” for severe C. Difficile colitis prior to the need for surgical intervention.

This is a preview of subscription content, log in via an institution.

References

  1. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:825–34. doi:10.1056/NEJMoa1408913.

  2. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet (Lond). 2005;366:1079–84. doi:10.1016/s0140-6736(05)67420-x.

    Article  CAS  Google Scholar 

  3. Hunter JC, Mu Y, Dumyati GK, Farley MM, Winston LG, Johnston HL, Meek JI, Perlmutter R, Holzbauer SM, Beldavs ZG, Phipps EC, Dunn JR, Cohen JA, Avillan J, Stone ND, Gerding DN, McDonald LC, Lessa FC. Burden of nursing home-onset Clostridium difficile Infection in the United States: estimates of incidence and patient outcomes. Open Forum Infect Dis. 2016;3(1):196. doi:10.1093/ofid/ofv196.

    Article  Google Scholar 

  4. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978;298:531–4. doi:10.1056/nejm197803092981003.

    Article  CAS  PubMed  Google Scholar 

  5. Blaser M, J. Missing microbes. London: Picador; 2015.

    Google Scholar 

  6. Kuy S, Jenkins P, Romero RA, Samra N, Kuy S. Increasing incidence of and increased mortality associated with Clostridium difficile-associated megacolon. JAMA Surg. 2016;151:85–6. doi:10.1001/jamasurg.2015.2677.

    Article  PubMed  Google Scholar 

  7. Freedberg DE, Salmasian H, Cohen B, Abrams JA, Larson EL. Receipt of antibiotics in hospitalized patients and risk for Clostridium difficile infection in subsequent patients who occupy the same bed. JAMA Intern Med. 2016;176(12):1801–8. doi:10.1001/jamainternmed.2016.6193.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol. 2011;32:387–90. doi:10.1086/659156.

    Article  PubMed  Google Scholar 

  9. Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pepin K, Chouinard D. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171:466–72. doi:10.1503/cmaj.1041104.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis. 2006;42:758–64. doi:10.1086/501126.

    Article  PubMed  Google Scholar 

  11. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433–41. doi:10.1056/NEJMoa051590.

    Article  CAS  PubMed  Google Scholar 

  12. Cowardin CA, Buonomo EL, Saleh MM, Wilson MG, Burgess SL, Kuehne SA, Schwan C, Eichhoff AM, Koch-Nolte F, Lyras D, Aktories K, Minton NP, Petri WA Jr. The binary toxin CDT enhances Clostridium difficile virulence by suppressing protective colonic eosinophilia. Nat Microbiol. 2016;1:16108. doi:10.1038/nmicrobiol.2016.108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Abt MC, McKenney PT, Pamer EG. Clostridium difficile colitis: pathogenesis and host defence. Nat Rev Microbiol. 2016;14:609–20. doi:10.1038/nrmicro.2016.108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Nolke T, Schwan C, Lehmann F, Ostevold K, Pertz O, Aktories K. Septins guide microtubule protrusions induced by actin-depolymerizing toxins like Clostridium difficile transferase (CDT). Proc Natl Acad Sci U S A. 2016;113:7870–5. doi:10.1073/pnas.1522717113.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Sartelli M, Malangoni MA, Abu-Zidan FM, Griffiths EA, Di Bella S, McFarland LV, Eltringham I, Shelat VG, Velmahos GC, Kelly CP, Khanna S, Abdelsattar ZM, Alrahmani L, Ansaloni L, Augustin G, Bala M, Barbut F, Ben-Ishay O, Bhangu A, Biffl WL, Brecher SM, Camacho-Ortiz A, Cainzos MA, Canterbury LA, Catena F, Chan S, Cherry-Bukowiec JR, Clanton J, Coccolini F, Cocuz ME, Coimbra R, Cook CH, Cui Y, Czepiel J, Das K, Demetrashvili Z, Di Carlo I, Di Saverio S, Dumitru IM, Eckert C, Eckmann C, Eiland EH, Enani MA, Faro M, Ferrada P, Forrester JD, Fraga GP, Frossard JL, Galeiras R, Ghnnam W, Gomes CA, Gorrepati V, Ahmed MH, Herzog T, Humphrey F, Kim JI, Isik A, Ivatury R, Lee YY, Juang P, Furuya-Kanamori L, Karamarkovic A, Kim PK, Kluger Y, Ko WC, LaBarbera FD, Lee JG, Leppaniemi A, Lohsiriwat V, Marwah S, Mazuski JE, Metan G, Moore EE, Moore FA, Nord CE, Ordonez CA, Junior GA, Petrosillo N, Portela F, Puri BK, Ray A, Raza M, Rems M, Sakakushev BE, Sganga G, Spigaglia P, Stewart DB, Tattevin P, Timsit JF, To KB, Trana C, Uhl W, Urbanek L, van Goor H, Vassallo A, Zahar JR, Caproli E, Viale P. WSES guidelines for management of Clostridium difficile infection in surgical patients. World J Emerg Surg. 2015;10:38. doi:10.1186/s13017-015-0033-6.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Bublin JG, Barton TL. Rectal use of vancomycin. Ann Pharmacother. 1994;28:1357–8.

    CAS  PubMed  Google Scholar 

  17. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478–498.; quiz 499. doi:10.1038/ajg.2013.4.

    Article  CAS  PubMed  Google Scholar 

  18. Al-Jashaami LS, DuPont HL. Management of Clostridium difficile infection. Gastroenterol Hepatol. 2016;12:609–16.

    Google Scholar 

  19. Arora V, Kachroo S, Ghantoji SS, Dupont HL, Garey KW. High Horn's index score predicts poor outcomes in patients with Clostridium difficile infection. J Hosp Infect. 2011;79:23–6. doi:10.1016/j.jhin.2011.04.027.

    Article  CAS  PubMed  Google Scholar 

  20. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422–31. doi:10.1056/NEJMoa0910812.

    Article  CAS  PubMed  Google Scholar 

  21. Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, Krulicki W. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clinical Infect Dis. 2012;55(Suppl 2):S132–42. doi:10.1093/cid/cis338.

    Article  CAS  Google Scholar 

  22. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clinical Infect Dis. 2003;36:580–5. doi:10.1086/367657.

    Article  Google Scholar 

  23. Armstrong GD, Pillai DR, Louie TJ, MacDonald JA, Beck PL. A potential new tool for managing Clostridium difficile infection. J Infect Dis. 2013;207:1484–6. doi:10.1093/infdis/jit069.

    Article  PubMed  Google Scholar 

  24. Aroniadis OC, Brandt LJ, Greenberg A, Borody T, Kelly CR, Mellow M, Surawicz C, Cagle L, Neshatian L, Stollman N, Giovanelli A, Ray A, Smith R. Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: a multicenter experience. J Clin Gastroenterol. 2016;50:398–402. doi:10.1097/mcg.0000000000000374.

    PubMed  Google Scholar 

  25. Bowman KA, Broussard EK, Surawicz CM. Fecal microbiota transplantation: current clinical efficacy and future prospects. Clin Exp Gastroenterol. 2015;8:285–91. doi:10.2147/ceg.s61305.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Apisarnthanarak A, Khoury H, Reinus WR, Crippin JS, Mundy LM. Severe Clostridium difficile colitis: the role of intracolonic vancomycin? Am J Med. 2002;112:328–9.

    Article  PubMed  Google Scholar 

  27. Nathanson DR, Sheahan M, Chao L, Wallack MK. Intracolonic use of vancomycin for treatment of clostridium difficile colitis in a patient with a diverted colon: report of a case. Dis Colon Rectum. 2001;44:1871–2.

    Article  CAS  PubMed  Google Scholar 

  28. Shetler K, Nieuwenhuis R, Wren SM, Triadafilopoulos G. Decompressive colonoscopy with intracolonic vancomycin administration for the treatment of severe pseudomembranous colitis. Surg Endosc. 2001;15:653–9. doi:10.1007/s004640080104.

    Article  CAS  PubMed  Google Scholar 

  29. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clinical Infect Dis. 2002;35:690–6. doi:10.1086/342334.

    Article  Google Scholar 

  30. Kim PK, Huh HC, Cohen HW, Feinberg EJ, Ahmad S, Coyle C, Teperman S, Boothe H. Intracolonic vancomycin for severe Clostridium difficile colitis. Surg Infect. 2013;14:532–9. doi:10.1089/sur.2012.158.

    Article  Google Scholar 

  31. Akamine CM, Ing MB, Jackson CS, Loo LK. The efficacy of intracolonic vancomycin for severe Clostridium difficile colitis: a case series. BMC Infect Dis. 2016;16:316. doi:10.1186/s12879-016-1657-1.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Seder CW, Villalba MR Jr, Robbins J, Ivascu FA, Carpenter CF, Dietrich M, Villalba MR Sr. Early colectomy may be associated with improved survival in fulminant Clostridium difficile colitis: an 8-year experience. Am J Surg. 2009;197:302–7. doi:10.1016/j.amjsurg.2008.11.001.

    Article  PubMed  Google Scholar 

  33. Carchman EH, Peitzman AB, Simmons RL, Zuckerbraun BS. The role of acute care surgery in the treatment of severe, complicated Clostridium difficile-associated disease. J Trauma Acute Care Surg. 2012;73:789–800. doi:10.1097/TA.0b013e318265d19f.

    Article  PubMed  Google Scholar 

  34. Nassour I, Carchman EH, Simmons RL, Zuckerbraun BS. Novel management strategies in the treatment of severe Clostridium difficile infection. Adv Surg. 2012;46:111–35.

    Article  PubMed  Google Scholar 

  35. Sailhamer EA, Carson K, Chang Y, Zacharias N, Spaniolas K, Tabbara M, Alam HB, DeMoya MA, Velmahos GC. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg (Chicago, IL, 1960). 2009;144:433–439.; discussion 439–40. doi:10.1001/archsurg.2009.51.

    Article  Google Scholar 

  36. Thai H, Guerron AD, Bencsath KP, Liu X, Loor M. Fulminant Clostridium difficile enteritis causing abdominal compartment syndrome. Surg Infect. 2014;15:821–5. doi:10.1089/sur.2013.026.

    Article  Google Scholar 

  37. van der Wilden GM, Chang Y, Cropano C, Subramanian M, Schipper IB, Yeh DD, King DR, de Moya MA, Fagenholz PJ, Velmahos GC. Fulminant Clostridium difficile colitis: prospective development of a risk scoring system. J Trauma Acute Care Surg. 2014;76:424–30. doi:10.1097/ta.0000000000000105.

    Article  PubMed  Google Scholar 

  38. Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg. 2011;254:423–427.; discussion 427–9. doi:10.1097/SLA.0b013e31822ade48.

    Article  PubMed  Google Scholar 

  39. Olivas AD, Umanskiy K, Zuckerbraun B, Alverdy JC. Avoiding colectomy during surgical management of fulminant Clostridium difficile colitis. Surg Infect. 2010;11:299–305. doi:10.1089/sur.2010.026.

    Article  Google Scholar 

  40. Waltz P, Zuckerbraun B. Novel therapies for severe Clostridium difficile colitis. Curr Opin Crit Care. 2016;22:167–73. doi:10.1097/mcc.0000000000000282.

    PubMed  Google Scholar 

  41. Arsan C, Gonzalez OY, Gillespie TL. A fatal case of Clostridium difficile enterocolitis following diverting loop ileostomy reversal. Surg Infect Case Rep. 2016;1:16–8. doi:10.1089/crsi.2016.29004.c.

    Article  Google Scholar 

  42. Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, Simmons RL. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235:363–72.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Byrn JC, Maun DC, Gingold DS, Baril DT, Ozao JJ, Divino CM. Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg (Chicago, IL, 1960). 2008;143:150–154.; discussion 155. doi:10.1001/archsurg.2007.46.

    Article  Google Scholar 

  44. Pepin J, Vo TT, Boutros M, Marcotte E, Dial S, Dube S, Vasilevsky CA, McFadden N, Patino C, Labbe AC. Risk factors for mortality following emergency colectomy for fulminant Clostridium difficile infection. Dis Colon Rectum. 2009;52:400–5. doi:10.1007/DCR.0b013e31819a69aa.

    Article  PubMed  Google Scholar 

  45. Fashandi AZ, Ellis SR, Smith PW, Hallowell PT. Overwhelming recurrent Clostridium difficile infection after reversal of diverting loop ileostomy created for prior fulminant C. difficile colitis. Am Surg. 2016;82:194–5.

    PubMed Central  Google Scholar 

  46. Ihnat P, Gunkova P, Peteja M, Vavra P, Pelikan A, Zonca P. Diverting ileostomy in laparoscopic rectal cancer surgery: high price of protection. Surg Endosc. 2016;30:4809–16. doi:10.1007/s00464-016-4811-3.

    Article  PubMed  Google Scholar 

  47. Ferrada P, Velopulos CG, Sultan S, Haut ER, Johnson E, Praba-Egge A, Enniss T, Dorion H, Martin ND, Bosarge P, Rushing A, Duane TM. Timing and type of surgical treatment of Clostridium difficile-associated disease: a practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2014;76:1484–93. doi:10.1097/ta.0000000000000232.

    Article  PubMed  Google Scholar 

  48. Brown CJ, Boutros M, Morris A, Divino CM. CAGS and ACS evidence based reviews in surgery. Is a diverting loop ileostomy and colonic lavage an alternative to colectomy for the treatment of severe Clostridium difficile-associated disease? Can J Surg. 2014;57:214–6.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Ferrada P, Callcut R, Zielinski MD, Bruns B, Yeh DD, Zakrison TL, Meizoso JP, Sarani B, Catalano RD, Kim PK, Plant V, Pasley A, Dultz LA and Haut ER. Loop Ileostomy Versus Total Colectomy As Surgical Treatment For Clostridium Difficile-Associated Disease: An Eastern Association for the Surgery of Trauma Multicenter Trial. Journal of Trauma and Acute Care Surg. 2017;83:36–40.

    Google Scholar 

  50. Lamontagne F, Labbe AC, Haeck O, Lesur O, Lalancette M, Patino C, Leblanc M, Laverdiere M, Pepin J. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg. 2007;245:267–72. doi:10.1097/01.sla.0000236628.79550.e5.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Longo WE, Mazuski JE, Virgo KS, Lee P, Bahadursingh AN, Johnson FE. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum. 2004;47:1620–6.

    Article  PubMed  Google Scholar 

  52. Sheitoyan-Pesant C, Abou Chakra CN, Pepin J, Marcil-Heguy A, Nault V, Valiquette L. Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection. Clin Infect Dis. 2016;62:574–80. doi:10.1093/cid/civ958.

    Article  CAS  PubMed  Google Scholar 

  53. Hermsen JL, Dobrescu C, Kudsk KA. Clostridium difficile infection: a surgical disease in evolution. J Gastrointest Surgery. 2008;12:1512–7. doi:10.1007/s11605-008-0569-9.

    Article  Google Scholar 

  54. To KB, Napolitano LM. Clostridium difficile infection: update on diagnosis, epidemiology, and treatment strategies. Surg Infect. 2014;15:490–502. doi:10.1089/sur.2013.186.

    Article  Google Scholar 

  55. Miller AT, Tabrizian P, Greenstein AJ, Dikman A, Byrn J, Divino C. Long-term follow-up of patients with fulminant Clostridium difficile colitis. J Gastrointest Surg. 2009;13:956–9. doi:10.1007/s11605-009-0819-5.

    Article  PubMed  Google Scholar 

  56. Koss K, Clark MA, Sanders DS, Morton D, Keighley MR, Goh J. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis. 2006;8:149–54. doi:10.1111/j.1463-1318.2005.00876.x.

    Article  CAS  PubMed  Google Scholar 

  57. Medich DS, Lee KK, Simmons RL, Grubbs PE, Yang HC, Showalter DP. Laparotomy for fulminant pseudomembranous colitis. Arch Surg (Chicago, IL, 1960). 1992;127:847–52. discussion 843–52

    Article  CAS  Google Scholar 

  58. Perera AD, Akbari RP, Cowher MS, Read TE, McCormick JT, Medich DS, Celebrezze JP Jr, Beck SJ, Fischer PE, Caushaj PF. Colectomy for fulminant Clostridium difficile colitis: predictors of mortality. Am Surg. 2010;76:418–21.

    PubMed  Google Scholar 

  59. Hall JF, Berger D. Outcome of colectomy for Clostridium difficile colitis: a plea for early surgical management. Am J Surg. 2008;196:384–8. doi:10.1016/j.amjsurg.2007.11.017.

    Article  PubMed  Google Scholar 

  60. Lee J, Tashjian DB, Moriarty KP. Is partial colectomy the operation of choice in pediatric Clostridium difficile colitis? Pediatr Surg Int. 2012;28:603–7. doi:10.1007/s00383-012-3097-3.

    Article  PubMed  Google Scholar 

  61. Nale JY, Spencer J, Hargreaves KR, Buckley AM, Trzepinski P, Douce GR, Clokie MR. Bacteriophage combinations significantly reduce clostridium difficile growth in vitro and proliferation in vivo. Antimicrob Agents Chemother. 2016;60:968–81. doi:10.1128/aac.01774-15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, Gerding DN, Kelly CP, Katchar K, Baxter R, Ambrosino D, Molrine D. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine. 2010;28:965–9. doi:10.1016/j.vaccine.2009.10.144.

    Article  CAS  PubMed  Google Scholar 

  63. Leuzzi R, Adamo R, Scarselli M. Vaccines against Clostridium difficile. Hum Vaccin Immunother. 2014;10:1466–77. doi:10.4161/hv.28428.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD Jr, Leney M, Sloan S, Hay CA, Ambrosino DM. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362:197–205. doi:10.1056/NEJMoa0907635.

    Article  CAS  PubMed  Google Scholar 

  65. Unger M, Eichhoff AM, Schumacher L, Strysio M, Menzel S, Schwan C, Alzogaray V, Zylberman V, Seman M, Brandner J, Rohde H, Zhu K, Haag F, Mittrucker HW, Goldbaum F, Aktories K, Koch-Nolte F. Selection of nanobodies that block the enzymatic and cytotoxic activities of the binary Clostridium difficile toxin CDT. Sci Rep. 2015;5:7850. doi:10.1038/srep07850.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–15. doi:10.1056/NEJMoa1205037.

    Article  PubMed  Google Scholar 

  67. Gerding DN, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A, Van Schooneveld TC, Pardi DS, Ramos A, Barron MA, Chen H, Villano S. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA. 2015;313:1719–27. doi:10.1001/jama.2015.3725.

    Article  PubMed  Google Scholar 

  68. Theriot CM, Koenigsknecht MJ, Carlson PE Jr, Hatton GE, Nelson AM, Li B, Huffnagle GB, ZL J, Young VB. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun. 2014;5:3114. doi:10.1038/ncomms4114.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, Sadowsky MJ, Khoruts A. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol. 2014;306:G310–9. doi:10.1152/ajpgi.00282.2013.

    Article  CAS  PubMed  Google Scholar 

  70. Grimm M, Rafael T. Intracolonic administration of vancomycin for Clostridium difficile infection. Nursing. 2014;44:58–60. doi:10.1097/01.NURSE.0000446632.85961.5a.

    Article  PubMed  Google Scholar 

  71. van der Wilden GM, Subramanian MP, Chang Y, Lottenberg L, Sawyer R, Davies SW, Ferrada P, Han J, Beekley A, Velmahos GC, de Moya MA. Antibiotic regimen after a total abdominal colectomy with ileostomy for fulminant Clostridium difficile colitis: a multi-institutional study. Surg Infect. 2015;16:455–60. doi:10.1089/sur.2013.153.

    Article  Google Scholar 

  72. Kautza B, Zuckerbraun BS. The surgical management of complicated Clostridium difficile infection: alternatives to colectomy. Surg Infect. 2016;17:337–42. doi:10.1089/sur.2016.006.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA

    Peter K. Kim & Sheldon Teperman

  2. University of Rochester Medical Center, Rochester, NY, USA

    Peng Zhao

Authors
  1. Peter K. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peng Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sheldon Teperman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter K. Kim .

Editor information

Editors and Affiliations

  1. Department of Surgery, Macerata Hospital, Macerata, Italy

    Massimo Sartelli

  2. University of Udine, Infectious Diseases Division , Udine, Italy

    Matteo Bassetti

  3. St James's University Hospital, Trinity Centre for Health Sciences , Dublin, Ireland

    Ignacio Martin-Loeches

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Cite this chapter

Kim, P.K., Zhao, P., Teperman, S. (2018). Evolving Treatment Strategies for Severe Clostridium difficile Colitis: Defining the Therapeutic Window. In: Sartelli, M., Bassetti, M., Martin-Loeches, I. (eds) Abdominal Sepsis. Hot Topics in Acute Care Surgery and Trauma. Springer, Cham. https://doi.org/10.1007/978-3-319-59704-1_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-59704-1_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-59703-4

  • Online ISBN: 978-3-319-59704-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation